Abstract

BackgroundThe Glycine N-acyltransferase (GLYAT) gene encodes a protein that catalyzes the transfer of acyl groups from acyl CoA to glycine, resulting in acyl glycine and coenzyme A. Aberrant GLYAT expression is associated with several malignant tumors, but its clinical importance in human breast cancer (BC), has yet to be fully addressed. This study aims to evaluate the clinical function of GLYAT in BC patients.MethodsGLYAT expression was determined by immune blot and immunohistochemistry in three BC cell lines and primary cancer tissues. The MDA-MB 231 cell line was used for GLYAT gene knockdown experiments while the MCF7 cell line for overexpression experiments. Colony formation experiments, soft agar experiments, and transwell assays were utilized for further inspection of cell proliferation and migration capabilities. Immunofluorescence and western blot were used to detect markers of the epithelial-mesenchymal transition (EMT) and changes in the PI3K/AKT/Snail pathway. The role of GLYAT in tumor growth and metastasis was also assessed in nude mice in vivo. Also, a correlation analysis was performed between clinicopathological features and GLYAT expression in BC patients.ResultsGLYAT was decreased in human BC tissues and cell lines. Functional analysis showed that knockdown of GLYAT augmented BC cell proliferation in vitro and in vivo. However, this phenomenon was reversed when GLYAT was overexpressed in the transfected cells. Moreover, downregulation of GLYAT promoted the migratory properties of BC cells, likely through the activation of PI3K/AKT/Snail signaling, which subsequently induced the EMT. IHC analysis indicated that GLYAT was decreased in human BC tissues and lower GLYAT expression was correlated with histological grade, tumor TNM stage, Ki-67 status, and poorer survival in BC patients. Furthermore, lower GLYAT expression seemed as an independent risk factor related to poor prognosis in BC patients based on Cox regression analyses.ConclusionOur findings demonstrate that downregulation of GLYAT expression in human breast cancer is correlated with EMT via the PI3K/AKT/Snail pathway and is also associated with histological grade, tumor TNM stage, Ki-67 status, and poor survival in breast cancer patients.

Highlights

  • Breast cancer (BC) amongst women has been on the rise and it is fast becoming the most common malignancy in this population [1]

  • The expression of Glycine N-acyltransferase (GLYAT) was not statistically significant change in other cancer types, besides Breast invasive carcinoma (BRCA), Liver hepatocellular carcinoma (LIHC) and Cholangio carcinoma (CHOL) (Supplementary Figure 1), which indicated that GLYAT may have specific function in breast cancer

  • Analysis of data published in another study in Nature [23] which compared mRNA expression levels of GLYAT in normal breast tissues with invasive ductal and invasive lobular carcinoma revealed that two breast carcinoma subtypes had lower GLYAT mRNA levels (Figure 1B)

Read more

Summary

Introduction

Breast cancer (BC) amongst women has been on the rise and it is fast becoming the most common malignancy in this population [1]. Chemoradiotherapy, endocrine therapy, and molecular targeted therapy have greatly improved the survival of BC patients, those with advanced BC are often left with very limited therapeutic options [4, 5]. The EMT participates in tumor invasion and metastasis through multiple pathways. Many studies have indicated the EMT is strongly linked to breast cancer development [11,12,13]. Aberrant GLYAT expression is associated with several malignant tumors, but its clinical importance in human breast cancer (BC), has yet to be fully addressed. This study aims to evaluate the clinical function of GLYAT in BC patients

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call